Table 2 The results of taking drugs in groups 1 and 2 with nonalcoholic steatohepatitis and concomitant obesity, mean ± SD
From: The efficacy of L-carnitine in patients with nonalcoholic steatohepatitis and concomitant obesity
Parameter | Group | T0 of treatment | T1 after the start of treatment | T2 after the start of treatment |
|---|---|---|---|---|
Total bilirubin, µmol/L | 1 | 41.72 ± 2.04* | 30.42 ± 3.80* | 19.82 ± 1.16 ** |
2 | 41.5 ± 1.96* | 25.1 ± 2.13** | 15.47 ± 0.99**/*** | |
ALT, U/L | 1 | 80.31 ± 8.40* | 50.62 ± 4.76*/** | 31.67 ± 2.08 ** |
2 | 79.60 ± 9.05* | 41.29 ± 3.5*/** | 21.33 ± 1.61**/*** | |
AST, U/L | 1 | 67.4 ± 5.22* | 47.26 ± 3.18*/** | 29.94 ± 1.73** |
2 | 67.75 ± 4.93* | 38.47 ± 3.04*/** | 22.5 ± 1.28**/*** | |
GGT, U/L | 1 | 60.54 ± 5.69* | 52.6 ± 3.4* | 38.2 ± 2.10** |
2 | 60.70 ± 5.93* | 40.11 ± 2.02*/**/*** | 27.76 ± 1.34**/*** | |
ALP, U/L | 1 | 156.23 ± 9.17* | 129.36 ± 7.44* | 98.56 ± 5.62*/** |
2 | 157.06 ± 8.8* | 101.22 ± 6.15*/**/*** | 76.09 ± 5.11**/*** | |
Thymol test, conventional units | 1 | 6.25 ± 0.18* | 4.28 ± 0.20*/** | 2.65 ± 0.13*/** |
2 | 6.30 ± 0.14* | 3.59 ± 0.13*/**/*** | 1.93 ± 0.09**/*** | |
Reduction in cholesterol levels, % | 1 2 | 0 0 | 14–18 17–25 | 19–23 21–29 |